Berberine Actually Restores GLP-1 in Obese Patients This is the part of the research that truly got my attention
This medication is only approved for use in the chronic phase of the disease, when the plaque can be felt on exam and for curvature greater than 30 degrees
(2021) "Once-Weekly Semaglutide in Adults with Overweight or Obesity" The New England Journal of Medicine, 384(11) 5
At three months, the incidence of gastroparesis was similar between the two groups
It helps support glutathione production, antioxidant balance, respiratory wellness, and the bodys ability to respond to oxidative stress
The SURMOUNT trials for tirzepatide showed average weight reductions of 2022% at the highest dose, while semaglutide's STEP trials documented 1518% average loss